Stay updated on Cabozantinib in RAI-Refractory DTC Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in RAI-Refractory DTC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in RAI-Refractory DTC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update or modification in the context of a Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting, a medical and healthcare-related study.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:47.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying the health conditions and prior treatments required for inclusion. This change provides more comprehensive information about the requirements for participation in the clinical trial.
    Difference
    62%
    Check dated 2024-05-22T21:24:09.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T23:17:32.000Z thumbnail image

Stay in the know with updates to Cabozantinib in RAI-Refractory DTC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in RAI-Refractory DTC Clinical Trial page.